Key Developments: BioScrip Inc (BIOS.O)

BIOS.O on Nasdaq

17 Apr 2015
Change (% chg)

$0.02 (+0.38%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

BioScrip raises $62.5 million in private placement of convertible preferred stock and announces plan for $20 million rights offering
Monday, 9 Mar 2015 09:34am EDT 

BioScrip Inc:Says sale of $62.5 million in Series A Convertible Preferred Stock to Coliseum Capital Management, LLC and affiliated funds.The Preferred Stock is convertible into 12,088,975 shares of BioScrip's common stock at conversion price of $5.17 per share, which was the closing price of BioScrip's common stock on NASDAQ Global Market on March 6.Dividends on the Preferred Stock will be payable quarterly at an annual rate of 8.5 pct if paid in cash or 11.5 pct if accrued.As part of the transaction, BioScrip issued to Coliseum Capital warrants for an aggregate of 3.6 million shares of BioScrip stock.Warrants for 1.8 million shares are exercisable at $5.295 per share and warrants for 1.8 million shares are exercisable at $6.596 per share.In addition, BioScrip intends to conduct a registered rights offering to allow all of BioScrip's existing stockholders of record, on date to be determined by the Board.The non-transferable right to purchase their pro rata share of $20.0 million of Preferred Stock and warrants on same terms as completed private placement to Coliseum Capital.Proceeds from private placement will be used primarily to reduce BioScrip's outstanding indebtedness.  Full Article

BioScrip announces resignation of Hai V. Tran as Chief Financial Officer
Wednesday, 4 Feb 2015 04:01pm EST 

BioScrip Inc:Announced that Hai V. Tran, Senior Vice President, Chief Financial Officer and Treasurer, has tendered his resignation, effective March 27, 2015, in order to pursue other opportunities.  Full Article

BioScrip Inc sees FY 2014 revenue guidance at high end of prior range
Wednesday, 5 Nov 2014 04:35pm EST 

BioScrip Inc:Says that revenue for FY 2014 is forecasted to be at high end of the company's guidance range of $940.0 million to $980.0 million.  Full Article

BioScrip, Inc announces auditor change - Form 8-K
Monday, 8 Sep 2014 05:00pm EDT 

BioScrip, Inc:Says on Sept. 2, 2014, it was notified by Ernst & Young LLP that it is resigning as the company’s independent public accounting firm effective after the company files its Form 10-Q for its fiscal quarter ending Sept. 30.Effective on Sept. 8, 2014, it approved the appointment of KPMG LLP to serve as the independent registered public accounting firm.  Full Article

BioScrip Inc sees FY 2014 revenue guidance at high end of prior range; reaffirms FY 2014 EBITDA guidance
Wednesday, 6 Aug 2014 04:30pm EDT 

BioScrip Inc:Projects that its FY 2014 revenue will be at high end of its guidance range of $940.0 mln to $980.0 mln and that its FY 2014 adjusted EBITDA will be in range of $55.0 mln to $60.0 mln.FY 2014 revenue of $966.2 mln - Thomson Reuters I/B/E/S.  Full Article

BioScrip Inc gives FY 2014 guidance above analysts' estimates
Thursday, 8 May 2014 10:55pm EDT 

BioScrip Inc:Sees FY 2014 revenue to be in a range of $940.0 million to $980.0 million.Sees FY 2014 Adjusted EBITDA will be in a range of $55.0 million to $60.0 million.FY 2014 revenue estimates of $713 mln -Thomson Reuters I/B/E/S.FY 2014 adjusted EBITDA estimates of $54 - Thomson Reuters I/B/E/S.  Full Article

LHC Group Inc completes acquisition of Deaconess HomeCare
Tuesday, 1 Apr 2014 07:00am EDT 

LHC Group Inc:Completes the transaction with BioScrip, Inc.To purchase two of BioScrip's operating subsidiaries, doing business as Deaconess HomeCare and Elk Valley Health Services, for $59.5 mln.Jones Walker LLP acted as LHC Group's legal advisor in connection with the transaction.  Full Article

BioScrip Inc to Sell Home Health Services Business to LHC Group, Inc
Monday, 3 Feb 2014 07:15am EST 

BioScrip Inc:Enters into a definitive agreement to sell its Home Health business, known as Deaconess HomeCare, to LHC Group, Inc.Says consideration for $60 mln in cash.Says net proceeds from the sale will be used to pay down debt.Says Cain Brothers & Co., LLC acted as BioScrip's financial advisor in connection with the transaction and Polsinelli PC acted as BioScrip's legal advisor.  Full Article

Saxena White P.A. Files Securities Fraud Class Action Against BioScrip, Inc
Monday, 18 Nov 2013 11:03am EST 

Saxena White P.A. announced that it has filed a securities fraud class action lawsuit in the United States District Court for the Southern District of New York against BioScrip, Inc. (BioScrip or the Company) and certain of the Company's executive officers and/or directors and underwriters. The class action is filed on behalf of investors who purchased or otherwise acquired BioScrip's common stock between August 8, 2011 and September 23, 2013, inclusive (the "Class Period"). The complaint brings forth claims for violations of the Securities Exchange Act of 1934. In addition, the class action complaint is also filed on behalf of investors who purchased BioScrip's common stock pursuant or traceable to the Company's Registration Statement and Prospectus ("Offering Documents") issued in connection with BioScrip's secondary public offerings during the Class Period. The complaint brings forth claims for violations of the Securities Act of 1933.  Full Article

BioScrip Inc Reaffirms FY 2013 Revenue Guidance; Lowers FY 2013 EBITDA Guidance
Wednesday, 6 Nov 2013 05:00pm EST 

BioScrip Inc announced that for fiscal 2013, it expects revenue to be in the range of $830.0 million to $850.0 million and believes its Adjusted EBITDA to be in the range of $50.0 million to $52.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $839 million and EBITDA of $55.0 million for fiscal 2013.  Full Article

Search Stocks